|
市場調查報告書
疫苗施打技術動向
Stakeholder Opinions: Vaccine administration technologies - Beyond needles
| 出版商 |
Datamonitor |
| 出版日期 |
2009年04月 |
商品編碼 |
85288 |
| 內容資訊 |
英文 162 pages |
| 價格 |
|
|
疫苗施打技術動向 是由出版商Datamonitor在2009年04月所出版的。
這份英文市場調查報告書包含162 pages 價格從美金3800起跳。
本報告書內容包括：疫苗施打技術開發動向調查分析、新施打系統開發的依據、潛在需求、開發課題、主要施打技術、市場機會及風險、利害關係人訪談後得到的各種見解總結。內容綱要摘記如下：
實施概要
疫苗施打系統的開發經過
新疫苗施打系統的開發依據
- 疫苗施打的潛在需求：先進國家・新興國家不同
- 利用針・針筒的疫苗施打：存在健康的風險
- 替代的疫苗施打技術：黏膜免疫反應・全身免疫反應能提供更好的保護
- 無痛施打替代方式可改善接受度
- 替代施打技術：排除・減少冷凍鏈的必要性
- 改善疫苗施打的操作性・速度
- 從行銷層面分析，疫苗施打具有高度競爭力的優點
新疫苗施打系統的課題
- 新施打系統的藥事相關路徑的複雜度
- 疫苗市場的寡占結構・不景氣造成提供給生物科技企業的資金減少的課題
- 疫苗施打相關分子機制的知識不足：成為新技術開發的障礙
- 成本限制：新疫苗施打系統的商業機會減少
- 疫苗施打的新技術開發
經皮疫苗施打
- 經皮疫苗施打
- 經皮貼布
- 微細針
- 無針固態・液態・粉體注射技術
黏膜疫苗施打
參考文獻
附錄
圖表
Abstract
Introduction
Novel vaccine administration technologies have the potential to improve
vaccine developers' commercial competitiveness and to increase vaccination
safety and convenience. This report assesses key strategies, technologies and
products for novel dermal and mucosal vaccine administration. It also provides
an overview of opportunities and challenges for the sector and a future
outlook.
Scope of this research
- In-depth analysis of key dermal and mucosal vaccine administration
technologies
- Thorough assessment of the potential for selected vaccine administration
technologies
- Review of industry and academic stakeholder opinions involved in the
vaccine administration sector
- In-depth discussion of key opportunities and risks for novel vaccine
administration technologies
Research and analysis highlights
Needle-free vaccine delivery into and through the skin is an important focus
of vaccine research, with key technologies including intradermal patches,
microneedles and needle-free liquid, solid and powder injectors. Recognizing
the skin as an important immunologic organ, researchers mainly hope for an
improved immune response using this approach.
The largest potential for success of mucosal vaccine delivery lies in oral and
intranasal administration, while pulmonary vaccination appears less promising
due concerns regarding safety and reliable dosing. Careful selection of
suitable indications for mucosal delivery routes will be key to success in
this challenging sector.
Antigen stability, safety and efficacy are the key hurdles for novel vaccine
administration technologies. In times of restricted healthcare budgets,
pricing and manufacturing costs of novel vaccine administration systems need
to be kept to a minimum. Only the careful selection of suitable indications
will offer a route to commercial success.
Key reasons to purchase this research
- Review profiles of key marketed and development-stage, dermal and mucosal
vaccine administration technologies and assess their future potential
- Gain insight into the current state of vaccine administration technologies
and their future opportunities and challenges
- Benefit from opinions of key industry and academic stakeholders in the
vaccine administration field
Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the vaccine administration market
- Related reports
- Upcoming related reports
BRIEF HISTORY OF THE DEVELOPMENT OF VACCINE ADMINISTRATION SYSTEMS
- Overview of past developments in the vaccine administration sector
RATIONALE FOR THE DEVELOPMENT OF NOVEL VACCINE ADMINISTRATION SYSTEMS
- Unmet needs regarding vaccine administration differ between the developed
and the developing world
- Vaccine delivery through needle / syringe injection is associated with
considerable health risks
- Alternative vaccine delivery technologies could provide better protection
through a combined mucosal / systemic immune response
- Compliance could be improved through painless delivery alternatives
- Alternative delivery technologies could reduce or eliminate the need for a
cold chain
- Increased ease of use and speed of vaccine delivery is a key achievable
for biodefense indications and mass vaccination campaigns
- From a marketing perspective, vaccine administration could become an
advantage in highly competitive segments of the vaccines market
CHALLENGES FOR NOVEL VACCINE ADMINISTRATION SYSTEMS
- The regulatory pathway for novel delivery systems is complicated
- The oligopoly structure of the vaccines market and the decreasing funding
for biotech companies as a result of the economic downturn represent further
challenges
- The limited knowledge of the molecular mechanisms linked to vaccine
administration hampers the development of new technologies
- Cost constraints could dent the commercial opportunity of novel vaccine
administration systems
- Various new technologies are currently in development for vaccine
administration
DERMAL VACCINE ADMINISTRATION
- Transdermal vaccine delivery
- General considerations
- Transdermal vaccine delivery systems
- Transdermal patches
- Key transdermal patch systems in development for vaccine administration
- Datamonitor assessment
- Microneedles
- Key microneedle-based systems in development for vaccine administration
- Datamonitor assessment
- Needle-free solid, liquid or powder injection technologies
- General considerations
- Key needle-free injection systems in development for vaccine
administration
- Datamonitor assessment
MUCOSAL VACCINE ADMINISTRATION
- Oral vaccine delivery
- General considerations
- Oral vaccine delivery systems
- Marketed and pipeline oral vaccines
- Datamonitor assessment
- Intranasal vaccine delivery
- General considerations
- Intranasal vaccine delivery systems
- Marketed and pipeline intranasal vaccines
- Datamonitor assessment
- Pulmonary vaccine delivery
- General considerations
- Pulmonary vaccine delivery systems
- Marketed and pipeline pulmonary vaccines
- Datamonitor assessment
BIBLIOGRAPHY
APPENDIX
- Contributing experts
- Academic key opinion leaders
- Industry key opinion leaders
- Conferences
TABLES
- Table: Summary of key vaccine administration technologies in development,
2009
- Table: Key transdermal patch technologies in active development for
vaccines, 2009
- Table: SWOT analysis - transdermal patch vaccine delivery systems
- Table: Key microneedle technologies in active development for vaccines
- Table: SWOT analysis - microneedle vaccine delivery systems
- Table: Key needle-free injector technologies in active development for
vaccines
- Table: SWOT analysis - needle-free injection vaccine delivery systems
- Table: Key marketed oral vaccines, April 2009
- Table: Key oral pipeline vaccines, April 2009
- Table: SWOT analysis - oral vaccine delivery systems
- Table: Key marketed and pipeline nasal vaccines, March 2009
- Table: SWOT analysis - nasal vaccine delivery systems, 2009
- Table: Comparison of different classes of pulmonary inhaler devices
- Table: Key pipeline pulmonary vaccines, March 2009
- Table: SWOT analysis - pulmonary vaccine delivery systems
FIGURES
- Figure: Key events in the history of vaccine administration
- Figure: Unmet needs in vaccine administration in the developed and
developing worlds
- Figure: Drivers and resistors for vaccine administration technology
development
- Figure: Overview of the development stage and expected market entry of key
physical vaccine delivery technologies, 2009- 2019
- Figure: Transdermal vaccine delivery
- Figure: Transdermal patch vaccine delivery
- Figure: Microneedle vaccine delivery
- Figure: Becton Dickinson - BD Soluvia
- Figure: 3M Drug Delivery Systems - Solid Microstructured Transdermal
System
- Figure: Nanopass - MicroPyramids
- Figure: Zosano Pharma' s ZP patch technology
- Figure: Needle-free injector vaccine delivery
- Figure: Glide Pharma' s Glide SDI
- Figure: PharmaJet' s liquid jet injector
- Figure: Mucosa-associated lymphoid tissue and aggregates
- Figure: Generation of immunity through mucosal vaccination
- Figure: Advantages and drawbacks of mucosal vaccination
- Figure: Annual sales of RotaTeq versus Rotarix, 2006- 08
- Figure: FluMist - vaccine sales in the US, 2004- 08
- Figure: FluMist - CDC and private sector costs/dose in the US, 2004- 08
|
